Baseline demographics and clinical characteristics of all patients within the ELN22 risk categories
| . | ELN22 FAV (n = 575) . | ELN22 INT (n = 410) . | ELN22 ADV (n = 585) . | Total (N = 1570) . | P value . |
|---|---|---|---|---|---|
| ELN17, n (%) | <.001 | ||||
| FAV | 502 (87.3%) | 79 (19.3%) | 14 (2.4%) | 595 (37.9%) | |
| INT | 60 (10.4%) | 255 (62.2%) | 98 (16.8%) | 413 (26.3%) | |
| ADV | 13 (2.3%) | 76 (18.5%) | 473 (80.9%) | 562 (35.8%) | |
| Age, y | <.001 | ||||
| Median | 51 | 55 | 61 | 56 | |
| Range | 18-85 | 18-85 | 18-89 | 18-89 | |
| Sex, n (%) | .671 | ||||
| Female | 272 (47.3%) | 201 (49.0%) | 270 (46.2%) | 743 (47.3%) | |
| Male | 303 (52.7%) | 209 (51.0%) | 315 (53.8%) | 827 (52.7%) | |
| ECOG | .045 | ||||
| miss, n | 92 | 66 | 107 | 265 | |
| >1, n (%) | 122 (25.3%) | 110 (32.0%) | 151 (31.6%) | 383 (29.3%) | |
| 0-1, n (%) | 361 (74.7%) | 234 (68.0%) | 327 (68.4%) | 922 (70.7%) | |
| AML ontogeny | <.001 | ||||
| miss, n | 3 | 4 | 11 | 18 | |
| de novo, n (%) | 539 (94.2%) | 351 (86.5%) | 415 (72.3%) | 1305 (84.1%) | |
| sAML, n (%) | 22 (3.8%) | 43 (10.6%) | 128 (22.3%) | 193 (12.4%) | |
| tAML, n (%) | 11 (1.9%) | 12 (3.0%) | 31 (5.4%) | 54 (3.5%) | |
| WBC, ×109/L | <.001 | ||||
| Median | 27.5 | 23.3 | 9.2 | 18.20 | |
| Range | 0.3-453.0 | 0.6-465.9 | 0.3-450.0 | 0.3-465.9 | |
| Hb, mmol/L | .039 | ||||
| Median | 5.90 | 5.95 | 5.80 | 5.897 | |
| Range | 2.35-12.90 | 2.29-14.50 | 2.30-15.60 | 2.29-15.60 | |
| PLT, ×109/L | .001 | ||||
| Median | 43 | 58 | 51 | 50 | |
| Range | 3-554 | 3-514 | 4-1043 | 3-1043 | |
| BMBs | <.001 | ||||
| Median, % | 63 | 68 | 56 | 62 | |
| Range, % | 6-96 | 8-100 | 5-100 | 5-100 | |
| PBBs | <.001 | ||||
| Median, % | 45 | 46 | 28 | 39 | |
| Range, % | 0-100 | 0-99 | 0-99 | 0-100 | |
| alloHCT | .052 | ||||
| All pts., n (%) | 179 (31.1%) | 151 (36.8%) | 174 (29.6%) | 504 (32.0%) | |
| CR1, n (%) | 96 (16.7%) | 70 (17.1%) | 72 (12.3%) | 238 (15.2%) | |
| Salvage, n (%) | 76 (13.2%) | 65 (15.9%) | 74 (12.6%) | 215 (13.7%) |
| . | ELN22 FAV (n = 575) . | ELN22 INT (n = 410) . | ELN22 ADV (n = 585) . | Total (N = 1570) . | P value . |
|---|---|---|---|---|---|
| ELN17, n (%) | <.001 | ||||
| FAV | 502 (87.3%) | 79 (19.3%) | 14 (2.4%) | 595 (37.9%) | |
| INT | 60 (10.4%) | 255 (62.2%) | 98 (16.8%) | 413 (26.3%) | |
| ADV | 13 (2.3%) | 76 (18.5%) | 473 (80.9%) | 562 (35.8%) | |
| Age, y | <.001 | ||||
| Median | 51 | 55 | 61 | 56 | |
| Range | 18-85 | 18-85 | 18-89 | 18-89 | |
| Sex, n (%) | .671 | ||||
| Female | 272 (47.3%) | 201 (49.0%) | 270 (46.2%) | 743 (47.3%) | |
| Male | 303 (52.7%) | 209 (51.0%) | 315 (53.8%) | 827 (52.7%) | |
| ECOG | .045 | ||||
| miss, n | 92 | 66 | 107 | 265 | |
| >1, n (%) | 122 (25.3%) | 110 (32.0%) | 151 (31.6%) | 383 (29.3%) | |
| 0-1, n (%) | 361 (74.7%) | 234 (68.0%) | 327 (68.4%) | 922 (70.7%) | |
| AML ontogeny | <.001 | ||||
| miss, n | 3 | 4 | 11 | 18 | |
| de novo, n (%) | 539 (94.2%) | 351 (86.5%) | 415 (72.3%) | 1305 (84.1%) | |
| sAML, n (%) | 22 (3.8%) | 43 (10.6%) | 128 (22.3%) | 193 (12.4%) | |
| tAML, n (%) | 11 (1.9%) | 12 (3.0%) | 31 (5.4%) | 54 (3.5%) | |
| WBC, ×109/L | <.001 | ||||
| Median | 27.5 | 23.3 | 9.2 | 18.20 | |
| Range | 0.3-453.0 | 0.6-465.9 | 0.3-450.0 | 0.3-465.9 | |
| Hb, mmol/L | .039 | ||||
| Median | 5.90 | 5.95 | 5.80 | 5.897 | |
| Range | 2.35-12.90 | 2.29-14.50 | 2.30-15.60 | 2.29-15.60 | |
| PLT, ×109/L | .001 | ||||
| Median | 43 | 58 | 51 | 50 | |
| Range | 3-554 | 3-514 | 4-1043 | 3-1043 | |
| BMBs | <.001 | ||||
| Median, % | 63 | 68 | 56 | 62 | |
| Range, % | 6-96 | 8-100 | 5-100 | 5-100 | |
| PBBs | <.001 | ||||
| Median, % | 45 | 46 | 28 | 39 | |
| Range, % | 0-100 | 0-99 | 0-99 | 0-100 | |
| alloHCT | .052 | ||||
| All pts., n (%) | 179 (31.1%) | 151 (36.8%) | 174 (29.6%) | 504 (32.0%) | |
| CR1, n (%) | 96 (16.7%) | 70 (17.1%) | 72 (12.3%) | 238 (15.2%) | |
| Salvage, n (%) | 76 (13.2%) | 65 (15.9%) | 74 (12.6%) | 215 (13.7%) |
ADV, adverse; BMBs, bone marrow blasts; CR1, first CR; ECOG, Eastern Cooperative Oncology Group performance status; FAV, favorable; Hb, hemoglobin; INT, intermediate; PBBs, peripheral blood blasts; PLT, platelet count; sAML, secondary AML; tAML, therapy-related AML; miss, missing.